P Pharming Group NV
P
Închisă
1.1 -2.57
Rezumat
Modificarea prețului
24h
Minim
1.096
Maxim
1.133
Venit | -10M -5.1M |
|---|---|
Vânzări | -36M 71M |
P/E Medie Sector | 55.3 51.415 |
EPS | 0.01 |
Marjă de profit | -7.196 |
Angajați | 407 |
EBITDA | -4.8M -2.1M |
Următoarele câștiguri | 30 iul. 2026 |
|---|
Capitalizare de piață | -227M 781M |
|---|---|
Deschiderea anterioară | 3.67 |
Închiderea anterioară | 1.1 |
Pharming Group NV Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
Pharming Group NV Așteptări
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Costul vânzărilor
Profit brut din vânzări
Cheltuieli cu dobânzile pe datorie
EBITDA
Profit operațional
$
Despre Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
